SR-17018

ID: sr17018

Aliases: G-protein-biased MOR agonist

Type: compound

Route/form: oral or route depends on studied product

Status: research

Evidence level: preclinical

Best data tier: non-human experimental

Support scope: non-human/mechanistic, review/regulatory

Source types: preclinical, review

Linked sources: 3

Broad outcomes: Pain / addiction / acute care

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• mu-opioid receptor agonist
• G protein-biased or low-efficacy MOR agonism

Optimization domains

• pain
• opioid
• withdrawal research

Research basis

• Preclinical data suggest unusual tolerance/dependence profile versus classic opioids.
• Important because optimization discussion is rising and can be dangerous.

Limits, risks, and missing evidence

• No approved human use; opioid receptor agonism carries dependence, respiratory, impairment, and overdose-adjacent risks.
• Bias claims may reflect partial agonism/low efficacy more than a simple safety switch.

Risk flags

• opioid
• dependence
• unapproved context
• high risk

Linked papers, labels, and reviews

1. G protein signaling-biased agonist at the mu-opioid receptor reverses morphine tolerance
   preclinical / pubmed_sr17018_tolerance_2019
   Mouse data for SR-17018.
2. Comparison of morphine, oxycodone and SR-17018 for tolerance and efficacy in mouse pain models
   preclinical / pubmed_sr17018_comparison_2020
   Preclinical comparative pain data.
3. Biased versus partial agonism in the search for safer opioid analgesics
   review / pmc_biased_opioid_review_2020
   Important caution on interpreting biased MOR agonists.